VPC
ATRA icon

Vestal Point Capital’s Atara Biotherapeutics ATRA Stock Holding History

Vestal Point Capital’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-94,085
Closed -$726K – 82
2025
Q2 		$726K Hold
94,085
– – 0.04% 69
2025
Q1 		$559K Sell
94,085
-30,915
-25% -$270K 0.04% 59
2024
Q4 		$1.66M Buy
125,000
+323
+0.3% +$3.4K 0.1% 69
2024
Q3 		$1.01M Buy
124,677
+12,677
+11% +$109K 0.08% 68
2024
Q2 		$952K Hold
112,000
– – 0.07% 58
2024
Q1 		$1.94M Buy
+112,000
New +$1.99M 0.16% 53

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vestal Point Capital's ATRA Position: Q3 2025 in Review

Vestal Point Capital sold out of Atara Biotherapeutics (ATRA) in Q3 2025, closing a stake of 94,085 shares — an estimated $726K sold.

Vestal Point Capital first reported a position in ATRA in Q1 2024 and held it in 6 quarters. The position peaked at $1.94M in Q1 2024. 37 funds tracked by Wall St. Rank hold ATRA as of Q3 2025.

  • Vestal Point Capital reported no remaining Atara Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Vestal Point Capital sold 94,085 Atara Biotherapeutics shares in Q3 2025, an estimated $726K.
  • Vestal Point Capital first reported a position in Atara Biotherapeutics in Q1 2024 and held it in 6 quarters.
  • Vestal Point Capital's Atara Biotherapeutics position peaked at $1.94M in Q1 2024.
  • 37 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2025.

Based on Vestal Point Capital's 13F filing for Q3 2025, filed 14 Nov 2025.